Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
International Breast Cancer Study Group

Abstract

Adjuvant tamoxifen has been shown to reduce relapse and mortality among node-positive post-menopausal breast cancer patients. The value of adding chemotherapy to tamoxifen is controversial. Between July 1986 and April 1993, 1,266 postmenopausal breast cancer patients with node-positive disease were randomly assigned to receive one of four adjuvant therapy regimens: (A) tamoxifen alone for 5 years; (B) tamoxifen plus three courses of early cyclophosphamide, methotrexate, and fluorouracil (CMF) on months 1, 2, and 3; (C) tamoxifen plus delayed single courses of CMF on months 9, 12, and 15; (D) tamoxifen plus early and delayed CMF on months 1, 2, 3, 9, 12, and 15. The two-by-two factorial design allowed two direct comparisons: early CMF (B and D) versus no early CMF (A and C), and delayed CMF (C and D) versus no delayed CMF (A and B). Estrogen receptor (ER) status was known for all patients and was used to stratify the randomization. A total of 1, 212 patients (96%) were eligible and assessable. The median follow-up duration was 60 months. The results of the two-by-two factorial comparisons were as follows: (1) early CMF added to tamoxifen significantly improved 5-year disease-free survival (DFS; 64% v 57%; hazards ratio [HR], 0.7...Continue Reading

Citations

Dec 9, 1997·Journal of the National Cancer Institute·B FisherR G Margolese
Jan 8, 1999·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·F K BöhlerW Rhomberg
Nov 12, 1998·Journal of the National Cancer Institute·A GoldhirschH J Senn
Jun 16, 1999·Endocrine Reviews·F Cosman, R Lindsay
Dec 28, 1999·Medical and Pediatric Oncology·E E Harris, L J Solin
Feb 19, 2002·The Journal of Pharmacy and Pharmacology·Eugene P GoldbergJames S Marotta
Jun 14, 2006·Critical Reviews in Clinical Laboratory Sciences·M J Duffy
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ExtermannG H Lyman
Jan 12, 1999·British Journal of Obstetrics and Gynaecology·M GülmezogluJ M Belizan
Aug 21, 2002·Breast Cancer Research and Treatment·Jennifer L MalinRobert Brook
Mar 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco ColleoniAron Goldhirsch
May 7, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernhard C PestalozziUNKNOWN International Breast Cancer Study Group
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A WilsR C Coombes
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R JakeszG Steger
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D CrivellariA Goldhirsch
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S CoatesA Goldhirsch
Jul 9, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aron GoldhirschHans-Jörg Senn
Apr 3, 2001·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Marie-Odile CarrèreAlain Brémond
Dec 8, 2009·Anti-cancer Drugs·Gunjan GakharThu Annelise Nguyen
Apr 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Per KarlssonArne Wallgren
Jan 14, 2018·Health and Quality of Life Outcomes·Chee Khoon LeeAlan S Coates
May 31, 2002·Expert Opinion on Pharmacotherapy·Tarek M Mekhail, Maurie Markman
Dec 24, 1997·Australian and New Zealand Journal of Medicine·R D Snyder
Sep 18, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GoldhirschH J Senn
Dec 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ColleoniC M Rudenstam
Sep 21, 2004·Breast Cancer Research and Treatment·Marzio E E SabbioniUNKNOWN Swiss Group for Clinical Cancer Research (SAKK)
Oct 2, 2001·Cancer Investigation·L F Hutchins, C L Arick
Nov 26, 1998·The New England Journal of Medicine·C K Osborne
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A WallgrenUNKNOWN International Breast Cancer Study Group Trials I through VII
Sep 8, 2004·Lancet·Bernard FisherUNKNOWN National Surgical Adjuvant Breast and Bowel Project randomised clinical trials
Apr 7, 2017·Disease Models & Mechanisms·Ross Cagan, Pablo Meyer
Oct 13, 1998·Cancer Treatment Reviews·G Y Locker
Apr 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B C PestalozziUNKNOWN International Breast Cancer Study Group (IBCSG)
Nov 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J HuoberB Thürlimann
Nov 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P KarlssonUNKNOWN International Breast Cancer Study Group
Feb 28, 2001·Journal of the American College of Surgeons·S E Singletary

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.